D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 128 Citations 49,991 552 World Ranking 1093 National Ranking 39


What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Internal medicine

Randy D. Gascoyne mostly deals with Lymphoma, Diffuse large B-cell lymphoma, Pathology, Cancer research and Internal medicine. His Lymphoma study integrates concerns from other disciplines, such as Molecular biology and Survival analysis. His Diffuse large B-cell lymphoma research incorporates themes from Immunohistochemistry, Gene expression profiling and Rituximab.

His Pathology research integrates issues from Chromosomal translocation and Cytogenetics. Randy D. Gascoyne has included themes like Reed–Sternberg cell, Cyclin D2, Germinal center, Regulation of gene expression and STAT protein in his Cancer research study. His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine.

His most cited work include:

  • Circos: An information aesthetic for comparative genomics (5678 citations)
  • Revised response criteria for malignant lymphoma (3306 citations)
  • The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma (3077 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Lymphoma, Internal medicine, Diffuse large B-cell lymphoma, Cancer research and Pathology. His Lymphoma research is multidisciplinary, incorporating perspectives in Molecular biology, Cancer and Germinal center. Randy D. Gascoyne interconnects Gastroenterology, Surgery and Oncology in the investigation of issues within Internal medicine.

His Oncology research includes elements of Survival rate, Clinical trial, Survival analysis and ABVD. Randy D. Gascoyne has researched Diffuse large B-cell lymphoma in several fields, including CHOP, BCL6 and Gene expression profiling. In his study, which falls under the umbrella issue of Cancer research, Cyclin D1 is strongly linked to Mantle cell lymphoma.

He most often published in these fields:

  • Lymphoma (54.90%)
  • Internal medicine (39.06%)
  • Diffuse large B-cell lymphoma (35.67%)

What were the highlights of his more recent work (between 2016-2021)?

  • Lymphoma (54.90%)
  • Diffuse large B-cell lymphoma (35.67%)
  • Cancer research (29.75%)

In recent papers he was focusing on the following fields of study:

Randy D. Gascoyne spends much of his time researching Lymphoma, Diffuse large B-cell lymphoma, Cancer research, Internal medicine and Oncology. The various areas that Randy D. Gascoyne examines in his Lymphoma study include Immunohistochemistry, BCL6, Gene, Somatic cell and Tumor microenvironment. His Diffuse large B-cell lymphoma research is included under the broader classification of Pathology.

His Cancer research research is multidisciplinary, relying on both Exome sequencing, Gene mutation, Mutation, Gene expression profiling and Germinal center. Internal medicine is frequently linked to Gastroenterology in his study. In his research, Venetoclax and Proportional hazards model is intimately related to International Prognostic Index, which falls under the overarching field of Oncology.

Between 2016 and 2021, his most popular works were:

  • Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma (524 citations)
  • CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas (124 citations)
  • A multiprotein supercomplex controlling oncogenic signalling in lymphoma (117 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Internal medicine

His primary areas of study are Lymphoma, Cancer research, Diffuse large B-cell lymphoma, Internal medicine and Gene. Randy D. Gascoyne mostly deals with International Prognostic Index in his studies of Lymphoma. His research in Cancer research intersects with topics in Exome sequencing, Gene mutation, Mutation, Cancer and Germinal center.

His Diffuse large B-cell lymphoma study combines topics from a wide range of disciplines, such as B-cell receptor, Molecular classification, Bruton's tyrosine kinase and Syk. His research integrates issues of Gastroenterology and Oncology in his study of Internal medicine. Randy D. Gascoyne combines subjects such as Molecular biology, Gene rearrangement and Fluorescence in situ hybridization with his study of BCL6.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Circos: An information aesthetic for comparative genomics

Martin I Krzywinski;Jacqueline E Schein;Inanc Birol;Joseph Connors.
Genome Research (2009)

5811 Citations

Revised response criteria for malignant lymphoma

Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne.
Journal of Clinical Oncology (2007)

4527 Citations

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

Andreas Rosenwald;George Wright;Wing C. Chan;Wing C. Chan;Joseph M. Connors.
The New England Journal of Medicine (2002)

4208 Citations

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Christine P. Hans;Dennis D. Weisenburger;Timothy C. Greiner;Randy D. Gascoyne.
Blood (2004)

3955 Citations

Stromal gene signatures in large-B-cell lymphomas

G Lenz;G Wright;S S Dave;W Xiao.
The New England Journal of Medicine (2008)

1597 Citations

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells

Sandeep S. Dave;George Wright;Bruce Tan;Andreas Rosenwald;Andreas Rosenwald.
The New England Journal of Medicine (2004)

1486 Citations

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

Morin Rd;Johnson Na;Severson Tm;Mungall Aj.
Nature Genetics (2010)

1467 Citations

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Thomas M. Habermann;Edie A. Weller;Vicki A. Morrison;Randy D. Gascoyne.
Journal of Clinical Oncology (2006)

1446 Citations

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

R. Eric Davis;Vu N. Ngo;Georg Lenz;Pavel Tolar.
Nature (2010)

1430 Citations

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Ryan D Morin;María Méndez-Lago;Andrew J Mungall;Rodrigo Goya.
Nature (2011)

1369 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Randy D. Gascoyne

L. Jeffrey Medeiros

L. Jeffrey Medeiros

The University of Texas MD Anderson Cancer Center

Publications: 232

Stephen M. Ansell

Stephen M. Ansell

Mayo Clinic

Publications: 218

Elias Campo

Elias Campo

University of Barcelona

Publications: 213

Gilles Salles

Gilles Salles

Memorial Sloan Kettering Cancer Center

Publications: 210

Pier Luigi Zinzani

Pier Luigi Zinzani

University of Bologna

Publications: 194

Reiner Siebert

Reiner Siebert

University of Ulm

Publications: 189

Andreas Rosenwald

Andreas Rosenwald

University of Würzburg

Publications: 180

Stefano Pileri

Stefano Pileri

European Institute of Oncology

Publications: 178

Wolfram Klapper

Wolfram Klapper

Kiel University

Publications: 174

Emanuele Zucca

Emanuele Zucca

Universita della Svizzera Italiana

Publications: 158

Hervé Tilly

Hervé Tilly

Inserm : Institut national de la santé et de la recherche médicale

Publications: 155

Eric D. Hsi

Eric D. Hsi

Cleveland Clinic

Publications: 151

Miguel A. Piris

Miguel A. Piris

Instituto de Salud Carlos III

Publications: 149

Elaine S. Jaffe

Elaine S. Jaffe

National Institutes of Health

Publications: 145

Martin Dreyling

Martin Dreyling

Ludwig-Maximilians-Universität München

Publications: 143

Thomas M. Habermann

Thomas M. Habermann

Mayo Clinic

Publications: 142

Something went wrong. Please try again later.